Shanghai Henlius Biotech Inc

02696

Company Profile

  • Business description

    Shanghai Henlius Biotech Inc is a biopharmaceutical company in China with the vision to offer affordable and biologics for patients with a focus on oncology and autoimmune diseases. The Group is engaged in biopharmaceutical R&D, biopharmaceutical services, and biopharmaceutical production and sales. It operates in Mainland China, Asia Pacific (excluding Mainland China), North America, South America, Oceania, and Europe. The company products include HLX01 Rituximab, HLX02(trastuzumab), and others.

  • Contact

    B8 Building, No. 188 Yizhou Road
    11th Floor
    Xuhui District
    Shanghai200233
    CHN

    T: +86 2133395800

    https://www.henlius.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    4,082

Stocks News & Analysis

stocks

Overvalued ASX share has overly ambitious profit target

We think the new profit target is aggressive and unlikely to be met.
stocks

7 undervalued US stocks that crushed earnings

Arista and GE Vernova remain among the cheapest Morningstar-covered stocks after strong earnings beats.
stocks

Undervalued ASX share hitting on all cylinders

Strong performance across all segments in latest earnings release.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,165.4039.10-0.42%
CAC 408,352.0016.91-0.20%
DAX 4026,598.64151.31-0.57%
Dow JONES (US)51,583.73763.82-1.46%
FTSE 10010,881.5521.01-0.19%
HKSE23,753.84116.240.49%
NASDAQ24,513.53622.75-2.48%
Nikkei 22559,662.021,480.33-2.42%
NZX 50 Index14,303.77130.090.92%
S&P 5007,413.23148.44-1.96%
S&P/ASX 2009,044.7037.50-0.41%
SSE Composite Index3,602.5731.78-0.87%

Market Movers